??
由于中國政府重申扶持和促進(jìn)中醫(yī)藥產(chǎn)業(yè)的發(fā)展，中醫(yī)藥制造商正在大規(guī)模拓展全球市場。
據(jù)公司相關(guān)負(fù)責(zé)人表示，我國最大的特許制藥商廣州白云山醫(yī)藥集團(tuán)將設(shè)立2億元（約合3千萬美元）基金，用于在未來5年內(nèi)拓展中醫(yī)藥海外市場。
廣州白云山醫(yī)藥集團(tuán)副總經(jīng)理王文楚表示，這項基金將主要用于中醫(yī)藥產(chǎn)業(yè)海外注冊，全球市場運作以及國際合作。
上海掛牌公司在上個月與一家尼日利亞公司簽署了合作協(xié)議，這為之后的發(fā)展取得了良好的開端。
據(jù)北京同仁堂(集團(tuán))有限責(zé)任公司副總經(jīng)理丁永玲表示，這家老字號的中藥生產(chǎn)商，也正在擴(kuò)大其全球影響力。
丁永玲說，同仁堂已經(jīng)在全球25個國家和地區(qū)開設(shè)了115家藥店，另外，該公司可能還會考慮在海外市場收購更多的本地藥店、診所以及其他傳統(tǒng)中醫(yī)藥公司。
全國人大常委會正在審議我國首部《中醫(yī)藥法(草案)》，隨后政府作出了扶持中醫(yī)藥產(chǎn)業(yè)發(fā)展的最新承諾。國聯(lián)證券分析師劉生平表示，該法將有助于中醫(yī)藥企業(yè)為全球范圍內(nèi)的患者提供更多產(chǎn)品。
不過，由于文化和政策差異，中醫(yī)藥企業(yè)走向國際化仍會面臨一些挑戰(zhàn)。（中國進(jìn)出口網(wǎng)）
Traditional Chinese medicine (TCM) makers are expanding their presence in the global markets in a big way, as the government reiterated its support to further strengthen the sector.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, the largest patent drugmaker in China, is setting up a 200 million yuan ($30.87 million) fund to expand its overseas TCM presence in the next five years, according to company officials.
The fund will be mainly used for the overseas registration of TCM products, global market operations and international cooperation, said Wang Wenchu, deputy general manager of Guangzhou Baiyunshan.
The Shanghai-listed company has already made a good start by signing a cooperation agreement with a Nigerian company last month.
Beijing Tong Ren Tang Group Co Ltd, a time-honored TCM producer, is also expanding its global presence, said Ding Yongling, deputy general manager of group.
Tong Ren Tang already runs 115 medicine stores in 25 countries and regions, said Ding, adding that the company may consider more acquisitions in overseas markets like local medicine stores, clinics and other TCM companies.
The latest support commitment from the government comes close on the heels of the draft of China's first TCM law being discussed by the Standing Committee of the National People's Congress. The law will help TCM companies provide more products to patients globally, said Liu Shengping, an analyst from Guolian Securities.
But there are still some challenges for China's TCM firms to go global because of the cultural and policy differences.
